Recent advances in the isolation, culture and expansion of human B cells and the recovery of genes encoding immunoglobulin (Ig) are enabling the isolation of large numbers of antibodies to be used for probing the humoral immune response and developing diagnostics and therapeutics. The history of these advances and the use of these techniques were recently described in a comprehensive review 1 . For several decades, mouse monoclonal antibodies were isolated using the hybridoma technology 2 . However, the therapeutic application of these antibodies was limited by induction of anti-mouse antibodies and autoreactivity. More recently, monoclonal antibodies have been isolated through phage display libraries produced from humans with a humoral response of interest 3, 4 . Although this technique has produced numerous useful antibodies, its applicability is limited by differences in binding properties between antibodies expressed in bacterial and eukaryotic cells. In addition, phage display may result in heavy-and lightchain combinations that do not occur in the same B cell in vivo. Human B cells have also been immortalized by electrofusion 5 or Epstein-Barr virus (EBV) transformation [6] [7] [8] , with or without the use of toll-like receptor ligands. However, these techniques can be inefficient in some patients, such as those with HIV infection, and transformed clones can be lost because of instability.
In studies published since 2008, direct cloning of Ig-encoding genes from isolated B cells and their expression as monoclonal antibodies have bypassed many of these limitations and enabled the isolation of antibodies that are particularly rare or difficult to clone 9, 10 . This technique involves PCR amplification of Ig-encoding genes from B cells, cloning them into an expression vector and re-expression in 293T cells. To produce human monoclonal antibodies with a given specificity, two methods have been applied to isolate B cell populations of interest. In the first approach, plasmablasts have been isolated from the peripheral blood of infected or vaccinated patients 11 . This technique relies on the expansion of antigen-specific B cells within the plasmablast population in the peripheral blood 5-7 d after infection or vaccination.
In the second approach, fluorescently labeled antigens have been used to stain and sort antigen-specific memory B cells before cloning. HIV envelope (Env) trimers have been used for this purpose to isolate broadly neutralizing antibodies to HIV-1 (refs. 12,13) . Similarly, the broad and potent HIV-neutralizing antibody VRC01 was cloned using modified Env antigens. Peripheral blood B cells were stained with both a resurfaced core Env (RSC3) and a RSC with a point mutation in the CD4-binding site. Implementation of this technique made possible the isolation of cells specific for the CD4-binding sites that were used in expression cloning. However, for some antigens, such as HIV Env, there is considerable nonspecific background binding to B cells or other cells. Furthermore, only a small subset of B cells that bind a given antigen may have the effector function of interest. The use of modified antigens, such as RSC3, also requires prior knowledge of the specificity of interest.
In 2009, HIV-specific human monoclonal antibodies were isolated using an approach that enabled the examination of a broader range of peripheral blood B cells 14 . In that study, memory B cells were sorted, plated at a density of 1.3 cells per well, expanded in vitro with the addition of feeder cells and conditioned medium generated from mitogen-stimulated human T cells, and then the supernatants were screened for neutralization using a high-throughput technique 14 . The genes encoding Ig were then cloned from wells with neutralizing activity. In theory, this strategy enables researchers to isolate a large variety of antibodies with an effector function of interest without prior knowledge of specificity. However, the method for the isolation and in vitro expansion of B cells has remained proprietary. Recently, broadly neutralizing influenza hemagglutinin-specific antibodies were isolated from vaccinated or recently infected patients using IL-6 in microculture of sorted plasma cells 15 . In another study, researchers cultured eight cells per well after EBV transformation and plated the cultured cells with CD40L-expressing cells, a TLR9 agonist and a CHK2 kinase inhibitor 8 . However, implementation of this Isolation of monoclonal antibodies is an important technique for understanding the specificities and characteristics of antibodies that underlie the humoral immune response to a given antigen. Here we describe a technique for isolating monoclonal antibodies from human peripheral blood mononuclear cells. the protocol includes strategies for the isolation of switch-memory B cells from peripheral blood, the culture of B cells, the removal of the supernatant for screening and the lysis of B cells in preparation for immunoglobulin heavy-chain and light-chain amplification and cloning. We have observed that the addition of cytokines Il-2, Il-21 and irradiated 3t3-mscD40l feeder cells can successfully stimulate switch-memory B cells to produce high concentrations of IgG in the supernatant. the supernatant may then be screened by appropriate assays for binding or for other functions. this protocol can be completed in 2 weeks. It is adaptable to use in other species and enables the efficient isolation of antibodies with a desired functional characteristic without prior knowledge of specificity.
method potentially raises the same concerns noted above regarding the efficiency and stability of EBV transformation of B cells isolated from patients with HIV infection. Thus, there continues to be a need in the field for more widely applicable techniques for the isolation of monoclonal antibodies.
Our goal was to develop a simple, high-throughput method to isolate and expand memory B cells from peripheral blood mononuclear cells (PBMCs) that did not require transformation, fusion, transduction or activated T cell supernatant, and which produced at least 10 ng ml −1 of secreted IgG, the threshold for our microneutralization screening assay. Recently, we developed a technique in which peripheral blood B cells are plated in 384-well plates, similarly to the strategy noted above, and then B cells are stimulated and expanded over 13 d of culture. It is a major challenge for previously frozen primary B cells to survive culture at near-clonal density for up to 2 weeks and to overcome their highly proapoptotic state after activation 16 . To overcome this challenge, we tested multiple conditions known to enhance B cell survival or proliferation, including adding any of the following to the culture medium: insulin, transferrin, selenium, lactoferrin, Z-VAD, 1,2-bis The technique uses a negative isolation strategy that limits activation-induced cell death. This approach also enables the isolation of cells with low expression levels of surface IgG, such as plasmablasts . Cells are then stimulated to proliferate and produce IgG by culturing with CD40L-expressing feeder cells and IL-2, as well as IL-21, a potent inducer of antibody-secreting plasma cells 17 . We optimized the concentration of each of these components individually and in combination to maximize the concentrations of IgG produced (typically 0.2-1 µg ml −1 ). In our experience, when four cells per well are plated, we observe an average of 76% of wells that contain more than 10 ng ml −1 of IgG. This yield translates into a 77% efficiency overall, on the basis of a Poisson distribution predicting that 98% of wells would receive a minimum of one B cell. In the wells that we have selected for cloning, we recover at least one heavy or light chain 100% of the time. In 24% of cases, we are able to recover a matching number of heavy and light chains. We recommend aiming to achieve seeding densities between 1.3 and 4 B cells per well. A higher density of B cells in microwells will reduce the number of plates needed to screen the same number of B cells; however, it will also increase the difficulties in antibody cloning, as all combinations of heavy and light chains obtained from a well must be paired and expressed to regenerate the natural heavy-and light-chain pairing. Thus, the choice of seeding density depends on the individual laboratory's ability to handle large numbers of B cell culture plates as well as its capacity for the downstream steps of cloning, protein expression and functional assays.
We have recently used this method to isolate the broad and potent HIV-specific neutralizing antibodies named 10E8 and 7H6 (ref. 18 ). This technique can be used for the isolation of peripheral blood B cells before expression cloning. Although it has been optimized for use in humans, it is probably readily adaptable to other species. This method of discovery of novel monoclonal antibodies, in combination with specificity mapping, crystal structure and next-generation sequencing, can be a powerful tool for the understanding of both the fundamental basis of an immune response to an antigen and the evolution of the response 19 .
The following protocol can be performed manually or with a robotic liquid transfer system. Typically, for a manual setup, twenty 384-well plates are used, and the timing below is for two experimenters working together. For a robotic setup, 60-80 plates may be used, depending on the yield of B cells from the PBMC sample. At the end of this protocol, supernatants may be collected for their use in a microneutralization assay or screening for other desired functions. •
MaterIals

REAGENTS
IL-21, 100 µg ml −1 Prepare 100 µg ml −1 IL-21 by dissolving 25 µg of IL-21 in 250 µl of (wt/vol) PBS.  crItIcal Freshly prepare the IL-21 solution each time. 3T3-msCD40L cell culture medium Prepare 3T3-msCD40L cell culture medium by adding 50 ml of FBS that has been heat inactivated at 56 °C for 40 min, 5 ml of l-glutamine and 500 µl of gentamicin into 450 ml of highglucose DMEM. Filter the medium with a Stericup filter unit. The medium can be stored at 4 °C for up to 2 weeks. IMDM medium Prepare IMDM medium by adding 50 ml of heat-inactivated FBS and 1 ml of MycoZap Plus-PR to 450 ml of IMDM with GlutaMAX, and then filter the medium with a Stericup filter unit. The medium can be stored at 4 °C for up to 2 weeks. B cell culture medium Prepare B cell culture medium by adding 3.5 ml of 10,000 U ml −1 IL-2, 175 µl of 100 µg ml −1 of IL-21 and 10 ml of 35 × 10 6 3T3-msCD40L cells to 336 ml of IMDM medium.  crItIcal Freshly prepare the medium each time. Lysis buffer To prepare lysis buffer for 20 plates, add 2 ml of 1 M Tris-HCl (pH 8.0) and 1. 
2|
Pellet the cells by centrifuging at 335g and 4 °C for 10 min.
3|
Resuspend the cells in 10 ml of 3T3-msCD40L cell culture medium. Add 30 µl of the cell suspension to 270 µl of Guava ViaCount. Count the cell number using Guava PCA.
4| Pellet the cells again as in
Step 2, and resuspend the cells at 10 × 10 6 ml −1 in 3T3-msCD40L cell culture medium. Place the 50-ml conical tube with the cells in the Gammacell 1000 chamber and irradiate the cells with 5,000 rads.
5|
After irradiation at room temperature, spin down the cells as in Step 2.
6|
Resuspend the cells in viable cell culture freezing medium and add 1-2 ml of medium in each cryovial with 35 × 10 6 cells per vial. Put the vials into a freezing container, store them at −80 °C overnight and, on the next day, transfer them to a liquid nitrogen freezer for long-term storage.  pause poInt The cells can be stored in liquid nitrogen for more than 2 years.
prestain cell treatment • tIMInG 1 h 7| Thoroughly clean the hood and pipettes with 70% (vol/vol) ethanol.
8|
Prepare at least 400 ml of IMDM medium.
9|
Prepare a staining master mix in a microcentrifuge tube: 50 µl of staining volume per 50 million cells. See below for details on the composition of a master mix for one sample. cell staining • tIMInG 1-2 h 11| Warm a 15-ml conical tube containing 7.5 ml of IMDM medium and 15 µl of benzonase to 37 °C in a water bath. Thaw a vial of 10-50 × 10 6 patient-derived PBMCs by warming it in a 37 °C water bath until floating ice is visible. Add 1 ml of the prewarmed IMDM/benzonase medium from the 15-ml conical tube to the vial; let the vials sit for 15 s. Move all contents to the 15-ml conical tube containing the warm medium.
12|
Centrifuge the conical tube at 335g and 4 °C for 10 min. 17| Cover all six tubes in foil and incubate them at 4 °C for 30 min.
18| Resuspend the cells with 1 ml of PBS-1% (wt/vol) BSA using a p1000. Mix the suspension well and add 2 ml more of PBS-1% (wt/vol) BSA. 
23|
Adjust the flow rate so that the event rate is as close as possible to 13,000 events per second but not higher. Monitor the flow rate during the sorting process.
24| Turn on the cell sorter 30 min before sorting to allow the lasers to warm up. Choose the gates as shown in Figure 1a for sorting.
25|
Pour 250 µl of IMDM medium in a 2-ml sterile microcentrifuge tube, vortex gently to wet the sides of the tube and load it onto the sort block.
26|
Begin sorting and collect ~30,000 B cells. This task takes ~20 min to complete. Record the flow data at some point during the sort.
27|
Unload the patient-derived PBMC sample and place the remaining sample on ice. Remove the sort tube from the sort block, and then use a pipette tip to gently wash down its sides using the medium in the tube.
28|
Clean the cell sorter to check the post-sort purity. Run the sample line backflush for 1-2 min, and then load a fresh tube of PBS-1% (wt/vol) BSA at flow rate 8 for 2 min to clean out residual cells in the lines.
29| Take a ~10-µl aliquot from the sorted sample and add it to 100 µl of PBS-1% (wt/vol) BSA in a flow tube. Thereafter, run a flow cytometry experiment on it and record the post-sort purity. 34| Centrifuge the cell suspensions at 335g for 10 min at 4 °C. Resuspend the resulting cell pellet in 10 ml of IMDM medium.
35|
Calculate the reagent amounts. For 20 plates, an arrangement that corresponds to an overall feeder mixture volume of 350 ml, the composition of the mixture is described in the following table:
component Volume
Complete IMDM medium 336 ml IL-2 (10,000 U ml −1 ) 3.5 ml IL-21 (100 µg ml − 1 ) 175 µl 3T3-msCD40L 10 ml 36| Prepare the feeder mixture as calculated in
Step 35 to achieve a confluent, single-cell layer of 5,000 fibroblasts per well.
37|
Set aside 25 ml of the mixture (corresponding to 20 plates) to be used as a 'no-B cell' (non-antibody) control.
plating B cells • tIMInG variable; 1-3 h 38|
Label the lids and sides of each plate with numbers and the sort date. Use 12-channel pipettes to plate the cells. Angled plate holders may be useful, if the cells are plated with a pipette.
39|
Add 100 µl of sterile dH 2 O to the outer wells (wells A1-A24, P1-P24, B1-O1 and B24-O24; ~7.7 ml of sterile dH 2 O are needed per plate).  crItIcal step Adding the sterile dH 2 O in the outer wells will diminish evaporation from the inner culture wells. Partial evaporation of medium in the inner wells can negatively affect B cell growth and survival.
40|
Before adding B cells to the feeder mixture, plate 50 µl per well of the feeder mix set aside in
Step 37 for the non-antibody control in row D of all plates.  crItIcal step The culture supernatants of row D will be collected after 13 d and used as no-IgG controls in neutralization screening and compared with the supernatants from other rows.
41|
Add an appropriate amount of B cells as calculated in
Step 32 to the remaining feeder mix.
42|
Move the cell mixture to large sterile basins, and plate 50 µl per well in the inner 308 wells (except row D).
43|
Ensure that you gently mix the cells in the basin frequently to keep the B cells evenly suspended. 49| Count the number of 384-well plates used for B cell culture that were collected on day 13 and label as many new 384-well plates.
50| Use 12-channel pipettes to move 40 µl of supernatant from each well of the old plates to a corresponding well on the new plates.  crItIcal step Make sure that you have plenty of tips on hand before you start.  crItIcal step To avoid disturbing the B cells, place the tips as far down into the wells as possible. A suitable approach to this task is to touch the bottom lightly, move the tips up slightly and then pull up the supernatants slowly to avoid aspirating B cells before dispensing into new plates.  crItIcal step If the collection process is performed robotically and the supernatants are intended for a microneutralization assay, transfer 20 µl to each of the two black opaque 384-well plates.
51|
Cover the plates to which the supernatants have been added with aluminized foil seals and put the lids on. (Fig. 1) , cells are plated into microculture. On day 13, supernatants are collected and screened for neutralization; IgG genes are cloned from positive wells and re-expressed. This protocol covers cell sorting, culturing and supernatant collection.
52| Store the supernatant plates at −80 °C for neutralization screening or an appropriate functional assay.  pause poInt The supernatant plates can be stored at −80 °C for up to 6 months.
53| Add 20 µl of lysis buffer to all wells containing B cells. Cover the plates with aluminized foil seals and put the lids on.
Immediately store the B cell lysis plates at −80 °C for future use in Ig gene amplification and cloning.  crItIcal step Take care not to touch the wells with the pipette tips to avoid well-to-well B cell contamination; change the tips when necessary. If robotics are being used, a 'blowout and tip touch' command can be programmed after the dispense command. In this case, the tip is above the plate and does not actually touch it. This command serves to jolt the tips to ensure that any adherent lysis buffer falls into the well.  pause poInt The B cell lysis plates can be stored at −80 °C for up to 2 years.
54|
Use cell supernatants to screen for secreted IgG, to test the binding specificity or neutralization or to implement other functional assays. Genes encoding Ig VH, Ig Vκ and Vλ from positive wells can be recovered using RT-PCR, cloned into IgG heavy-and light-chain expression vectors and expressed by transfection of 293T cells as described previously 9, 21 (Fig. 3) 
